The first new mechanism acne drug in 40 years has been launched in the United States.

Figure 1. The exact agent of Clascoterone's structural Clascoterone treatment for acne is unclear, but laboratory studies have shown that Clascoterone acts on androgen-infested bodies (AR) in sebum glands and hair follicles, inhibits the production of testosterone (DHT), a key driver of acne lesions, inhibits the secretion of sebum gland cell lipids, and reduces the release of pro-inflammatory cytokines.
, Clascoterone disrupts the pathogenesus of acne lesions due to reduced cytokines and lipids.
that Clascoterone itself does not lower DHT levels in the body, which effectively avoids the side effects of reducing DHT in the body.
1% approval of the
1% clascoterone cream was based on a key 12-month Clinical Phase III trial, the main endpoint of which was that the proportion of subjects in each treatment group was at least two percentage points lower than the baseline, the IGA score for week 12 was 0 (clear) or 1 (almost clear);
results showed that in week 52, 57% and 62% of the subjects achieved an improvement of more than two points in the researcher's overall score (IGA) to achieve skin symptom removal (0 points) or basic removal (1 point).
results showed that the duration and duration of local medication did not increase the occurrence of serious side effects.
adverse events associated with treatment were not recorded during the trial.
Casiopea is a pharmaceutical company specializing in the development and commercialization of prescription drugs with novel mechanisms to address long-standing underlying skin problems, in particular acne, androgen hair loss (AGA) and genital warts.
Clascoterone (7.5% concentration) solution for genetic hair loss, antibiotic CB-06-01 for acne, and immunomodulation agent CB-06-02 for genital warts.
acne treatment drug Acne is a chronic inflammatory skin disease, according to the China Acne Treatment Guidelines (revised 2019), the incidence rate of Chinese cross-sectional statistics is 8.1%.
study found that 95 percent of people develop acne to varying degrees.
50 million acne patients in the United States each year, and 5 million acne patients actively seek medical treatment.
expects the number of acne patients to increase by 6.5% by 2024.
for nearly 40 years, the market's growth has been severely thrmped by a lack of innovation in new product development.
1 external treatment drug for acne External medication is the basis for the treatment of acne, mild and moderate acne other than medication mainly.
1.1-dimensional A acid drug External vitamin A acid drugs can be used as a separate first-line drug for mild acne, commonly used drugs for all-trans-A acid, iso-dimensional A acid, third-generation vitamin A acid drug Adaparin and hezarotin.
1.2 antibacterial drug benzoyl peroxide: At present, the drug has no acne acetate resistance to appear, can be used as the preferred external drug for inflammatory acne.
antibiotics: including erythromycin, lincomycin and its derivatives Klinmycin, chlorampheniccin, chlorampheniccin and phosidic acid.
other: different concentrations and dosage forms of xylic acid, ammonia benzene, selenium disulfide, sulfur and salgin acid, etc.
2 Systemic treatment of acne 2.1 Antibacterial drugs: Antibacterial drugs against acne propylene acid bacteria are commonly used methods of moderate to severe acne, to pay attention to drug resistance, prohibit abuse.
preferred tyrencline classes such as minotin, docetonin and so on.
2.2 dimensional A acids: including oral A acids and veamines.
2.3 Hormone Therapy Anti-Androgen Therapy: Estrogen and progesterone, introesters, insulin boosters.
glucocorticoids: For explosive, polymeric acne and heavier inflammatory responses, choose pernisone or dexamisone therapy.
domestic anti-acne drug market statistics show that domestic sales of anti-acne drugs from 2012 to 2014 from 0.6 billion yuan has been growing to 0.72 billion yuan, a growth rate of 10%, in 2015 This is down from 2014 and has been growing steadily from 2016 to 2019, with sales of anti-acne drugs in sample hospitals in China amounting to 100 million yuan in 2019, up from about 240 million yuan nationwide.
2. Domestic sample hospital anti-acne drug sales in recent years, unit: RMB 100 million small compilation of several commonly used acne drugs in recent years sales, see Figure 4.
the chart, isovisyl A acid has the largest market share, followed by Adaparin, with benzoyl peroxide at the lowest.
sales of isovisyl A acid increased year by year, from 13.6 million in 2012 to 34 million in 2019, with the largest increase in 2018-2019, with a growth rate of 33.3%.
Adaparin has also been growing, from 12.4 million in 2012 to 20.5 million in 2019.
3. Domestic sample hospitals in recent years anti-acne small class drug sales, units: million yuan.